Disulfide-Modified Mesoporous Silica Nanoparticles for Biomedical Applications
Mesoporous silica nanoparticles (MSNs) are highly porous carriers used in drug and gene delivery research for biomedical applications due to their high surface area, narrow particle size distribution, and low toxicity. Incorporating disulfide (SS) bonds into the walls of MSNs (MSN-SSs) offers a dual...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Crystals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4352/13/7/1067 |
| _version_ | 1827733360059875328 |
|---|---|
| author | Melissa Venedicto Jake Carrier Ha Na Chen-Yu Chang Daniela R. Radu Cheng-Yu Lai |
| author_facet | Melissa Venedicto Jake Carrier Ha Na Chen-Yu Chang Daniela R. Radu Cheng-Yu Lai |
| author_sort | Melissa Venedicto |
| collection | DOAJ |
| description | Mesoporous silica nanoparticles (MSNs) are highly porous carriers used in drug and gene delivery research for biomedical applications due to their high surface area, narrow particle size distribution, and low toxicity. Incorporating disulfide (SS) bonds into the walls of MSNs (MSN-SSs) offers a dual pathway for drug release due to the pore delivery and collapsing porous structure after cellular engulfment. This study explores the effect of embedding disulfide bonds into MSNs through various structural and biological characterization methods. Raman spectroscopy is employed to detect the SS bonds, SEM and TEM for morphology analyses, and a BET analysis to determine the required amount of SSs for achieving the largest surface area. The MSN-SSs are further loaded with doxorubicin, an anticancer drug, to assess drug release behavior under various pH conditions. The MSN-SS system demonstrated an efficient pH-responsive drug release, with over 65% of doxorubicin released under acidic conditions and over 15% released under neutral conditions. Cleaving the SS bonds using dithiothreitol increased the release to 94% in acidic conditions and 46% in neutral conditions. Biocompatibility studies were conducted using cancer cells to validate the engulfment of the nanoparticle. These results demonstrate that MSN-SS is a feasible nanocarrier for controlled-release drug delivery. |
| first_indexed | 2024-03-11T01:10:19Z |
| format | Article |
| id | doaj.art-029318d22b4f41799fde2f9d4e440edf |
| institution | Directory Open Access Journal |
| issn | 2073-4352 |
| language | English |
| last_indexed | 2024-03-11T01:10:19Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Crystals |
| spelling | doaj.art-029318d22b4f41799fde2f9d4e440edf2023-11-18T18:53:58ZengMDPI AGCrystals2073-43522023-07-01137106710.3390/cryst13071067Disulfide-Modified Mesoporous Silica Nanoparticles for Biomedical ApplicationsMelissa Venedicto0Jake Carrier1Ha Na2Chen-Yu Chang3Daniela R. Radu4Cheng-Yu Lai5Department of Mechanical and Materials Engineering, Florida International University (FIU), Miami, FL 33174, USADepartment of Chemistry and Biochemistry, Florida International University (FIU), Miami, FL 33174, USADepartment of Mechanical and Materials Engineering, Florida International University (FIU), Miami, FL 33174, USADepartment of Mechanical and Materials Engineering, Florida International University (FIU), Miami, FL 33174, USADepartment of Mechanical and Materials Engineering, Florida International University (FIU), Miami, FL 33174, USADepartment of Mechanical and Materials Engineering, Florida International University (FIU), Miami, FL 33174, USAMesoporous silica nanoparticles (MSNs) are highly porous carriers used in drug and gene delivery research for biomedical applications due to their high surface area, narrow particle size distribution, and low toxicity. Incorporating disulfide (SS) bonds into the walls of MSNs (MSN-SSs) offers a dual pathway for drug release due to the pore delivery and collapsing porous structure after cellular engulfment. This study explores the effect of embedding disulfide bonds into MSNs through various structural and biological characterization methods. Raman spectroscopy is employed to detect the SS bonds, SEM and TEM for morphology analyses, and a BET analysis to determine the required amount of SSs for achieving the largest surface area. The MSN-SSs are further loaded with doxorubicin, an anticancer drug, to assess drug release behavior under various pH conditions. The MSN-SS system demonstrated an efficient pH-responsive drug release, with over 65% of doxorubicin released under acidic conditions and over 15% released under neutral conditions. Cleaving the SS bonds using dithiothreitol increased the release to 94% in acidic conditions and 46% in neutral conditions. Biocompatibility studies were conducted using cancer cells to validate the engulfment of the nanoparticle. These results demonstrate that MSN-SS is a feasible nanocarrier for controlled-release drug delivery.https://www.mdpi.com/2073-4352/13/7/1067mesoporous silica nanoparticlesdisulfide bond functionalitycontrolled-release drug deliverybiomaterialsnanocarrierscancer research |
| spellingShingle | Melissa Venedicto Jake Carrier Ha Na Chen-Yu Chang Daniela R. Radu Cheng-Yu Lai Disulfide-Modified Mesoporous Silica Nanoparticles for Biomedical Applications Crystals mesoporous silica nanoparticles disulfide bond functionality controlled-release drug delivery biomaterials nanocarriers cancer research |
| title | Disulfide-Modified Mesoporous Silica Nanoparticles for Biomedical Applications |
| title_full | Disulfide-Modified Mesoporous Silica Nanoparticles for Biomedical Applications |
| title_fullStr | Disulfide-Modified Mesoporous Silica Nanoparticles for Biomedical Applications |
| title_full_unstemmed | Disulfide-Modified Mesoporous Silica Nanoparticles for Biomedical Applications |
| title_short | Disulfide-Modified Mesoporous Silica Nanoparticles for Biomedical Applications |
| title_sort | disulfide modified mesoporous silica nanoparticles for biomedical applications |
| topic | mesoporous silica nanoparticles disulfide bond functionality controlled-release drug delivery biomaterials nanocarriers cancer research |
| url | https://www.mdpi.com/2073-4352/13/7/1067 |
| work_keys_str_mv | AT melissavenedicto disulfidemodifiedmesoporoussilicananoparticlesforbiomedicalapplications AT jakecarrier disulfidemodifiedmesoporoussilicananoparticlesforbiomedicalapplications AT hana disulfidemodifiedmesoporoussilicananoparticlesforbiomedicalapplications AT chenyuchang disulfidemodifiedmesoporoussilicananoparticlesforbiomedicalapplications AT danielarradu disulfidemodifiedmesoporoussilicananoparticlesforbiomedicalapplications AT chengyulai disulfidemodifiedmesoporoussilicananoparticlesforbiomedicalapplications |